** Shares of medical device maker VEEV.N down ~3% at
$172.4
** Company forecasts Q4 revenue between $620 mln to $622 mln
vs consensus of $623.5 mln
** FY guidance for sales of $2.353 bln to $2.355 bln, below
expectations of $2.362 bln
** Company posts Q3 revenue of $616.5 mln, in line with avg.
estimate of $615.1 mln
** At least four brokerages cut PT on VEEV after results,
outlook
** 17 out of 27 brokerages rate stock "buy" or higher, nine
"hold" and one "sell"; median PT: $212
** Up to last close, VEEV up ~11% YTD
(Reporting by Pavithra S in Bengaluru)
((pavithra.s@thomsonreuters.com))